Key Takeaways
- • Eurazeo closed its fifth-generation secondaries programme at €2.3 billion, exceeding its fundraising target, demonstrating continued institutional investor confidence in the firm's diversified private markets strategy.
- • The firm manages €39 billion in diversified assets under management, including €30 billion on behalf of institutional and private clients, positioning it as a leading global investment group with significant scale across European mid-market segments.
- • Eurazeo's strategic ambition for 2024-2027 is to become the leading private asset manager across European mid-market, growth, and impact investing, leveraging its integrated platform and multi-asset approach spanning private equity, private debt, real estate, and venture capital.
- • Recent portfolio exits include the sale of its stake in Spanish hotel group FST Hotels (completed 02/07/2026) and the sale of biotech company Memo Therapeutics AG to Ipsen for up to €700 million through Kurma Partners, a Eurazeo Group member.
- • Eurazeo has evolved from a single-strategy private equity firm into a diversified global investment manager with specialized capabilities in buyout, acceleration, venture, private debt (direct lending and asset-based finance), real estate, and infrastructure, reflecting broader industry shifts toward technology, healthcare, and sustainable infrastructure focus.
Summary
Eurazeo, a leading European asset manager in private markets, is advancing a diversified investment strategy that positions the firm to capitalize on evolving global market dynamics. The firm recently closed its fifth-generation secondaries programme at €2.3 billion, exceeding its original fundraising target, signaling robust institutional demand for secondaries exposure and validating the firm's ability to execute complex fund strategies. This fundraise reflects broader institutional appetite for mature asset redeployment and portfolio rationalization across European private markets.
The firm operates at substantial scale, managing €39 billion in diversified assets under management, with €30 billion deployed on behalf of institutional and private clients. This asset base reflects Eurazeo's transformation from a traditional single-strategy private equity operator into a multi-asset global investment manager. The strategic repositioning has been executed through the buildout of capabilities across private equity (spanning buyout, acceleration, and venture strategies), private credit (direct lending and asset-based finance), real estate (established in 2015), and growth-stage infrastructure investments.
Eurazeo's declared ambition for the 2024-2027 period, as articulated by co-CEOs Christophe Bavière and William Kadouch-Chassaing, is to become the leading private asset manager across European mid-market, growth, and impact investing. This positioning reflects the firm's conviction that mid-market European companies require tailored, innovative funding solutions that traditional banking infrastructure cannot provide. The firm's private equity team targets companies across development stages, from venture-backed disruptors to established market leaders requiring growth capital, while its private debt platform focuses on critical financing points for mid-cap companies.
Recent portfolio activity demonstrates active capital deployment and exit execution. Eurazeo completed the sale of its stake in Spanish hotel group FST Hotels and facilitated the sale of biotech company Memo Therapeutics AG to pharmaceutical company Ipsen for a transaction value potentially reaching €700 million through Kurma Partners, a Eurazeo Group member. These exits reflect successful value creation and strategic portfolio rotation consistent with the firm's broader transformation toward diversified private assets management, where it increasingly positions itself at the intersection of real estate and private equity, particularly in transition infrastructure opportunities.
The firm operates at substantial scale, managing €39 billion in diversified assets under management, with €30 billion deployed on behalf of institutional and private clients. This asset base reflects Eurazeo's transformation from a traditional single-strategy private equity operator into a multi-asset global investment manager. The strategic repositioning has been executed through the buildout of capabilities across private equity (spanning buyout, acceleration, and venture strategies), private credit (direct lending and asset-based finance), real estate (established in 2015), and growth-stage infrastructure investments.
Eurazeo's declared ambition for the 2024-2027 period, as articulated by co-CEOs Christophe Bavière and William Kadouch-Chassaing, is to become the leading private asset manager across European mid-market, growth, and impact investing. This positioning reflects the firm's conviction that mid-market European companies require tailored, innovative funding solutions that traditional banking infrastructure cannot provide. The firm's private equity team targets companies across development stages, from venture-backed disruptors to established market leaders requiring growth capital, while its private debt platform focuses on critical financing points for mid-cap companies.
Recent portfolio activity demonstrates active capital deployment and exit execution. Eurazeo completed the sale of its stake in Spanish hotel group FST Hotels and facilitated the sale of biotech company Memo Therapeutics AG to pharmaceutical company Ipsen for a transaction value potentially reaching €700 million through Kurma Partners, a Eurazeo Group member. These exits reflect successful value creation and strategic portfolio rotation consistent with the firm's broader transformation toward diversified private assets management, where it increasingly positions itself at the intersection of real estate and private equity, particularly in transition infrastructure opportunities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.